Mirzapoiazova Tamara, Lennon Frances E, Mambetsariev Bolot, Allen Michael, Riehm Jacob, Poroyko Valeriy A, Singleton Patrick A
Department of Medicine, Section of Pulmonary and Critical Care, Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA.
Department of Medicine, Section of Hematology/Oncology, Pritzker School of Medicine, The University of Chicago, Chicago, IL, USA.
Int J Cell Biol. 2015;2015:481493. doi: 10.1155/2015/481493. Epub 2015 Sep 10.
Defects in vascular integrity are an initiating factor in several disease processes. We have previously reported that high molecular weight hyaluronan (HMW-HA), a major glycosaminoglycan in the body, promotes rapid signal transduction in human pulmonary microvascular endothelial cells (HPMVEC) leading to barrier enhancement. In contrast, low molecular weight hyaluronan (LMW-HA), produced in disease states by hyaluronidases and reactive oxygen species (ROS), induces HPMVEC barrier disruption. However, the mechanism(s) of sustained barrier regulation by HA are poorly defined. Our results indicate that long-term (6-24 hours) exposure of HMW-HA induced release of a novel type of extracellular vesicle from HLMVEC called enlargeosomes (characterized by AHNAK expression) while LMW-HA long-term exposure promoted release of exosomes (characterized by CD9, CD63, and CD81 expression). These effects were blocked by inhibiting caveolin-enriched microdomain (CEM) formation. Further, inhibiting enlargeosome release by annexin II siRNA attenuated the sustained barrier enhancing effects of HMW-HA. Finally, exposure of isolated enlargeosomes to HPMVEC monolayers generated barrier enhancement while exosomes led to barrier disruption. Taken together, these results suggest that differential release of extracellular vesicles from CEM modulate the sustained HPMVEC barrier regulation by HMW-HA and LMW-HA. HMW-HA-induced specialized enlargeosomes can be a potential therapeutic strategy for diseases involving impaired vascular integrity.
血管完整性缺陷是多种疾病进程的起始因素。我们之前报道过,高分子量透明质酸(HMW-HA)是体内主要的糖胺聚糖,可促进人肺微血管内皮细胞(HPMVEC)中的快速信号转导,从而增强屏障功能。相比之下,在疾病状态下由透明质酸酶和活性氧(ROS)产生的低分子量透明质酸(LMW-HA)会导致HPMVEC屏障破坏。然而,HA对屏障进行持续调节的机制尚不清楚。我们的结果表明,HMW-HA长期(6-24小时)暴露会诱导HLMVEC释放一种新型细胞外囊泡,称为扩大体(以AHNAK表达为特征),而LMW-HA长期暴露则促进外泌体的释放(以CD9、CD63和CD81表达为特征)。这些效应可通过抑制富含小窝蛋白的微区(CEM)形成来阻断。此外,通过膜联蛋白II siRNA抑制扩大体释放可减弱HMW-HA对屏障的持续增强作用。最后,将分离的扩大体暴露于HPMVEC单层可增强屏障功能,而外泌体则导致屏障破坏。综上所述,这些结果表明,来自CEM的细胞外囊泡的差异释放调节了HMW-HA和LMW-HA对HPMVEC屏障的持续调节。HMW-HA诱导的特殊扩大体可能是治疗涉及血管完整性受损疾病的潜在策略。